Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
According to two new myeloma staging systems, multiple myeloma is about RISK. To be more specific, your diagnostic criteria all point to your risk of survival as well as your:
I am a long-term myeloma survivor myself. And let me tell you that I agree that managing MM is all about determining and then managing your RISK. And the importance of figuring out your level of risk as early in the process as possible.
Measuring risk in newly diagnosed multiple myeloma involves assessing various factors to determine the prognosis and guide treatment decisions. Several tools and criteria are commonly used by healthcare professionals for risk stratification in multiple myeloma. Here are some key factors considered:
If you’ve been diagnosed with MM then you’ve probably gone through a dizzying amount of diagnostic testing. Thought it is not fun to be stuck, scanned, poked, etc, etc. it is important for the NDMM patient to understand how far MM diagnostics have come and how the patient’s diagnostic information can:
To be more specific and read world, understanding your stage and prognosis will help you decide how aggressive you want to be with your therapies. By this I mean that if you are say, early stage with a low MM burden, you can undergo less therapy, expose your body to less toxicity and risk few if any side effects.
On the other hand, if you have advanced and high-risk MM, you may decide to treat your blood cancer more aggressively
If you would like to think through your choices, stages, and risks, email me at David.PeopleBeatingCancer@gmail.com
In the meantime, hang in there-
“Two proposed new multiple myeloma staging systems offer similar prognostic accuracy compared with the standard staging system, but the new systems provide more refined risk classifications across different disease stages…
Mohyuddin and his colleagues retrospectively compared the standard Revised International Staging System (R-ISS) with two newer systems, the Second Revision of the R-ISS (R2-ISS) and the Mayo Additive Staging System (MASS), using real-world data from nearly 500 patients with newly diagnosed multiple myeloma…
“Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model… In this study, we revised the R-ISS by analyzing the additive value of each single risk feature, including 1q+”
“Risk stratification in multiple myeloma is important for prognostication, patient selection for clinical trials, and comparison of treatment approaches. We developed and validated a staging system that incorporates additional FISH abnormalities not included in the R-ISS and reflects the additive effects of co-occurring high-risk disease features…
Among 1327 evaluable patients, OS was
in patients with
high-risk factors, respectively.